Eli Lilly (LLY) Reports Strong Phase 1 Ovarian Cancer Data

Eli Lilly (NYSE: LLY) reported new Phase 1 data for Sofe-M plus bevacizumab in platinum-sensitive ovarian cancer patients. The regimen showed a high confirmed response rate and disease control rate in both PARP inhibitor-experienced and naïve groups. Investigators observed consistent benefit across different FRa expression levels with no major new safety signals reported for Sofe-M. The Sofe-M and bevacizumab Phase 1 results in ovarian cancer are a fresh factor to weigh against our broader...